Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.
This session is open to all thinking about their next steps (specifically those looking to pursue an international career in industry) to find out more about the systems, recruitment processes, and type of roles available in other countries by hearing about the experience of, and advice from, alumni who have done it themselves.
This session will be held online via Zoom Webinar. Attendee visibility is disabled to other attendees and you should submit any questions to the host via the Q&A function. Confirmed panellists are:
Laabiah joined the Crick in 2018 on the PhD programme where her Immunology research investigated B-cell receptor signalling in B-cell lymphomas. She is now based in Singapore where she is Co-Founder of Ephia Bio. Here, Laabiah is working on building the future of personalized medicine by enabling therapies that target the 80% of disease-driving proteins hidden inside cells—targets conventional biologics can’t reach with an AI-driven platform that predicts patient-specific intracellular targets, unlocking personalized and semi-personalized therapeutics for diseases that currently lack treatment options.
Lúcia Moreira Teixeira is an Immunology Lead at Sanofi Vaccine R&D with over 15 years of international experience across academia, biotech, and pharma in Portugal, France, and the UK. She completed her PhD in Paris and Porto, focusing on mechanisms of immunoregulation and immunotherapy, before pursuing postdoctoral research in infectious diseases and tuberculosis immunology at ICVS in Portugal and at NIMR in London, later joining The Crick at its inauguration.
She subsequently transitioned into industry in 2020, holding scientific leadership roles at Freeline Therapeutics and Achilles Therapeutics in the fields of gene therapy and T cell therapies, before returning to France to join Sanofi, where she now leads immunology strategy and cross-functional scientific collaborations for innovative vaccine programs
Jan is a computational biologist working in cancer research. In academia, he studied expression of retroelements as promoters and exons. At the Crick, he worked as a Postdoc in George Kassiotis lab on assembling cancer transcriptomes and immunopeptidomes, and opportunities for therapeutic applications. He is now at Hoffmann La-Roche Research and Early Development (Basel), where his work bridges computational biology, statistics, biomarker data collection, and enabling decision making in drug discovery.
Hannah completed her PhD in Rickie Patani’s lab, researching the pathogenic events driving astrocyte dysfunction in hiPSC-derived models of ALS. She then moved into biotech venture capital at SCI Ventures in London, where she assessed therapeutic strategies for spinal cord injury and contributed to two investments within her first six months. She now works as an Associate at Biovance Capital, Portugal’s only dedicated biotech VC fund, based in Lisbon
